Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Report 2026

Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Overview

• Messenger Ribonucleic Acid (mRNA) Capping Enzyme market size has reached to $1.02 billion in 2025 • Expected to grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1% • Growth Driver: Rising Adoption Of Personalized Medicine Driving Growth Of The Market Due To Advances In Genetic Testing And Targeted Therapies • Market Trend: Launches Of Next-Generation Cap Analogs To Enhance Translation Efficiency And Streamline mRNA Manufacturing • North America was the largest region in 2025.

What Is Covered Under Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market?

Messenger ribonucleic acid (mRNA) capping enzyme is a vital enzyme that modifies newly synthesized mRNA molecules in eukaryotic cells. It adds a special chemical structure called the 5' cap to the beginning of the mRNA strand soon after it is transcribed from DNA. This capping step involves attaching a modified guanine nucleotide to the mRNA through an unusual 5’-5’ linkage. The main product types of messenger ribonucleic acid (mRNA) capping enzymes include recombinant messenger ribonucleic acid (mRNA) capping enzymes and natural messenger ribonucleic acid (mRNA) capping enzymes. Recombinant mRNA capping enzymes are genetically engineered proteins that selectively catalyze the capping of RNA molecules. It is applied for research and development, therapeutics, diagnostics, and others by several end-users, including pharmaceutical and biotechnology companies, research institutions, and contract manufacturing organizations (CMOs).

What Is The Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Growth Forecast?

The messenger ribonucleic acid (mrna) capping enzyme market size is expected to see rapid growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing development of mrna-based therapeutics, rising investments in advanced vaccine platforms, expansion of biopharmaceutical manufacturing infrastructure, growing demand for high-purity mrna components, increasing focus on scalable mrna production. Major trends in the forecast period include increasing demand for high-efficiency mrna capping enzymes, rising adoption of enzymatic mrna modification techniques, growing integration of mrna therapeutic manufacturing, expansion of recombinant enzyme production, enhanced focus on cap structure optimization.

Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Segmentation

1) By Product Type: Recombinant Messenger Ribonucleic Acid (mRNA) Capping Enzymes, Natural Messenger Ribonucleic Acid (mRNA) Capping Enzymes 2) By Application: Research And Development, Therapeutics, Diagnostics, Other Applications 3) By End-User: Pharmaceutical And Biotechnology Companies, Research Institutions, Contract Manufacturing Organizations (CMOS) Subsegments: 1) By Recombinant Messenger Ribonucleic Acid (mRNA) Capping Enzymes: Vaccinia Capping Enzyme (VCE), RNA Triphosphatase, Guanylyltransferase, (Guanine-N7)-Methyltransferase 2) By Natural Messenger Ribonucleic Acid (mRNA) Capping Enzymes: Cap 0 Capping Enzymes, Cap 1 Capping Enzymes, Cap 2 Capping Enzymes

What Is The Driver Of The Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market?

The growing adoption of personalized medicine is expected to propel the growth of the messenger ribonucleic acid (mRNA) capping enzyme market going forward. Personalized medicine is a healthcare approach that customizes medical treatment based on a person’s unique genetic makeup, lifestyle, and environmental influences. The adoption of personalized medicine is rising due to advancements in genetic testing technologies, which enable more accurate identification of individual patient needs, allowing for targeted and effective treatments. mRNA capping enzymes are beneficial for personalized medicines as they improve the stability and proper function of therapeutic mRNA, ensuring it is efficiently translated into proteins tailored to an individual’s treatment needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, marking a significant increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the messenger ribonucleic acid (mRNA) capping enzyme industry.

Key Players In The Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market

Major companies operating in the messenger ribonucleic acid (mrna) capping enzyme market are Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Takara Bio Inc., Aldevron, New England Biolabs Inc., CellScript Inc., Krishgen Biosystems, Yeasen Biotechnology Co. Ltd., Novoprotein Scientific Inc., TriLink Biotechnologies LLC, Jena Bioscience GmbH, OZ Biosciences, SBS Biotech Ltd., Vazyme Biotech Co. Ltd., Enzynomics Inc., Creative Enzymes, Canvax Biotech SL, APExBIO Technology LLC, BOC Sciences, KACTUS Biosystems.

Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Trends and Insights

Major companies operating in the mRNA capping enzyme market are increasingly focusing on next‑generation cap analog technologies, such as co‑transcriptional cap analogs, to enhance mRNA stability, translation efficiency, and therapeutic efficacy. Co‑transcriptional cap analogs are chemically modified molecules added to mRNA during its synthesis to mimic the natural 5′ cap, improving mRNA stability and protein production. For instance, in May 2023, TriLink Bio Technologies Inc., a US-based life sciences company, introduced CleanCap M6 analog, offering higher protein expression compared to enzymatically capped mRNA, high capping efficiency in a simplified one-pot reaction that accelerates mRNA production, and reduced manufacturing costs due to lower reagent and process requirements. These technology features have high AU capping efficiency with reduced reagent usage, significantly minimizing double-stranded RNA byproducts to improve mRNA safety and effectiveness. It also delivers higher yields of fully capped, long-template self-amplifying mRNA, lowering manufacturing costs and streamlining the production process.

What Are Latest Mergers And Acquisitions In The Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market?

In February 2025, TriLink BioTechnologies, a US-based biotechnology company, partnered with Aldevron to integrate CleanCap mRNA capping technology into Aldevron’s mRNA development and manufacturing services. Through this partnership, Aldevron aims to enhance mRNA yield, accelerate processing, and deliver higher-quality therapeutic solutions by leveraging TriLink’s CleanCap analogs, including CleanCap M6, AG 3′OMe, AG, and AU, which provide over 95% capping efficiency and improved expression levels. Aldevron is a US-based contract development and manufacturing organization (CDMO).

Regional Insights

North America was the largest region in the messenger ribonucleic acid (mRNA) capping enzyme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market?

The messenger ribonucleic acid (mRNA) capping enzyme market consists of sales of inorganic pyrophosphatase, murine RNase inhibitor, and polymerase chain reaction enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Report 2026?

The messenger ribonucleic acid (mrna) capping enzyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) capping enzyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.